Three new studies from the Centers for Disease Control and Prevention (CDC) show that vaccines are resistant to Delta disease. According to three published studies, Covid-19 vaccines are highly resistant to the highly contagious coronavirus. Friday by the Centers for Disease Control and Prevention.
The new information comes just a day after President Biden announced a large-scale guide to vaccines - the government's toughest action to prevent vaccines to save lives. About 80 million eligible Americans have not yet received the free available vaccine. Meanwhile, fires in the Nile Delta have raged across the country since June, triggering one of the biggest shifts of COVID-19 to date. The US is currently seeing approximately 150,000 new cases per day, with 100,000 hospitalizations and more than 1,500 deaths per day - nearly all of which could be prevented by vaccination. Delta has raised concerns about the vaccine's efficacy, as data has shown that the vaccines are well-maintained. The efficacy of the current vaccine against infection has been somewhat reduced due to the spread of Delta disease, but vaccination still provides powerful protection - both in hospital and actually dying from the disease.
In one of three public health studies, researchers reviewed data from more than 600,000 adult COVID-19 cases in 13 US jurisdictions over two time periods: the pre-delta period from April 4 to June 19 And beyond - the delta period from June 20 to July 17. The researchers then calculated the age ratios of cases, hospitalizations and deaths between the full and unvaccinated periods in both periods. The pre-delta period, compared to the unvaccinated period (95% confidence interval 7.8 to 15.8). This percentage decreased to 4.6% in the post-delta period (95% confidence interval 2.5 to 8.5). In the hospital compared with the unvaccinated (confidence interval 11.3 to 15.6). After delta, this ratio decreased slightly and was up to 10 times less likely (CI 8.1 to 13.3). Full vaccination was 16.6 times less likely to die before delta (confidence interval 13.5 to 20.4) and 11.3 times less likely to die after delta (confidence interval 9.1 to 13.9). The study authors concluded that the findings are "consistent with the potential reduction in vaccine protection against SARS-CoV-2 infection and the robust protection against hospitalization and death from COVID-19."
Additional data, taking into account vaccine coverage in two time periods, the authors calculated a rough estimate of how the effect of the vaccine changed in the two time periods. To protect the vaccine from infection, they estimated that its effectiveness decreased from 91% to 78% with delta. To protect against hospitalization, efficacy increased from 92% to 90% and in death from 94% to 91%.
One concern was that the decline in protection was more pronounced in the older age groups, with people over 65 experiencing a more severe decline. That finding was reflected in a second study conducted Friday by the CDC, which examined nearly 33,000 adults infected with the coronavirus. 19 cases from hospitals, emergency departments and emergency clinics. In this analysis, the effect of post-delta vaccination on hospitalization appears to be about 86%. However, when the researchers divided the data by age, the effect of the vaccine on hospitalization was 89% in people ages 18 to 74, but only 76% in people 75 or older. In a third, smaller study of more than 1,000 people at five veterans medical centers, researchers again observed a reduction in vaccine efficacy by age. Overall, vaccines are 87% effective in preventing admission to Delta Hospital. 95% hospitalization protection was exceptional for people aged 18-64 - but only 80% for people 65 or older.
At present, it is not clear whether the rate of decline in the studies was due to the strength of the delta type, poor protection over time from the initial vaccination, or the extent of both. However, the data released today will be crucial in future decisions regarding the timing and availability of magnified imaging in the United States. The Biden administration has announced that it is ready to provide booster doses to all 12-year-olds Americans. It starts from the twentieth week of September. However, the FDA has yet to sign — and there have been reports of internal frustration from the regulator over the government's initial plans. In addition, the Centers for Disease Control and Prevention's advisory committee, which sets official guidelines for the use of vaccines, has not scheduled another meeting until September 29 and will raise more questions about upcoming booster decisions.
Unvaccinated people are 5 times more likely to develop delta and 11 times more likely to die
NASA has asked industry for ideas to develop an "Artemis Crew ...
Welcome to 4.17 Missile Report! After the successful completion of Mission Inspiration...